221 related articles for article (PubMed ID: 28390432)
1. Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease.
Xu Y; Wang Y; Zhi J; Qi L; Zhang T; Li X
BMC Pharmacol Toxicol; 2017 Apr; 18(1):28. PubMed ID: 28390432
[TBL] [Abstract][Full Text] [Related]
2. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
3. The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease.
Sun YM; Wang LF; Li J; Li ZQ; Pan W
Eur J Clin Pharmacol; 2009 Feb; 65(2):157-61. PubMed ID: 18854995
[TBL] [Abstract][Full Text] [Related]
4. Effect of Cytochrome P450 7A1 (CYP7A1) Polymorphism on Lipid Responses to Simvastatin Treatment.
Liu N; Yang G; Liu Y; Hu M; Cai Y; Hu Z; Jia C; Zhang M
J Cardiovasc Pharmacol; 2020 Feb; 75(2):168-173. PubMed ID: 31663874
[TBL] [Abstract][Full Text] [Related]
5. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
Heath KE; Gudnason V; Humphries SE; Seed M
Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
[TBL] [Abstract][Full Text] [Related]
6. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Isles CG; Paterson JR
QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
[TBL] [Abstract][Full Text] [Related]
7. The effects of age and gender on the relationship between HMGCR promoter-911 SNP (rs33761740) and serum lipids in patients with coronary heart disease.
Akadam-Teker B; Kurnaz O; Coskunpinar E; Daglar-Aday A; Kucukhuseyin O; Cakmak HA; Teker E; Bugra Z; Ozturk O; Yilmaz-Aydogan H
Gene; 2013 Oct; 528(2):93-8. PubMed ID: 23933271
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
[TBL] [Abstract][Full Text] [Related]
9. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events.
Michelena HI; Osorio LA; Citkowitz E
Int J Cardiol; 2005 May; 101(1):111-4. PubMed ID: 15860392
[TBL] [Abstract][Full Text] [Related]
10. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
11. The Association Between Extracellular Matrix Metalloproteinase Inducer Polymorphisms and Coronary Heart Disease: A Potential Way to Predict Disease.
Weng Y; Chen T; Ren J; Lu D; Liu X; Lin S; Xu C; Lou J; Chen X; Tang L
DNA Cell Biol; 2020 Feb; 39(2):244-254. PubMed ID: 31928425
[TBL] [Abstract][Full Text] [Related]
12. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
März W; Wollschläger H; Klein G; Neiss A; Wehling M
Am J Cardiol; 1999 Jul; 84(1):7-13. PubMed ID: 10404843
[TBL] [Abstract][Full Text] [Related]
13. Association of Polymorphisms of the Matrix Metalloproteinase 9 Gene with Ischaemic Stroke in a Southern Chinese Population.
Li Y; Chen L; Yao S; Chen J; Hu W; Wang M; Chen S; Chen X; Li S; Gu X; Ma G; Zhao B; Zhong W; Li K
Cell Physiol Biochem; 2018; 49(6):2188-2199. PubMed ID: 30257242
[TBL] [Abstract][Full Text] [Related]
14. Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia.
Li J; Wang X; Zhang Z; Zou J; Chen Y; Wang X; Wu J
Curr Med Res Opin; 2014 Feb; 30(2):223-8. PubMed ID: 24156754
[TBL] [Abstract][Full Text] [Related]
15. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
Ansell BJ; Navab M; Hama S; Kamranpour N; Fonarow G; Hough G; Rahmani S; Mottahedeh R; Dave R; Reddy ST; Fogelman AM
Circulation; 2003 Dec; 108(22):2751-6. PubMed ID: 14638544
[TBL] [Abstract][Full Text] [Related]
18. Association of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin.
Liu N; Yang G; Hu M; Cai Y; Hu Z; Jia C; Zhang M
Pharmacogenomics; 2018 Sep; 19(14):1125-1132. PubMed ID: 30024814
[TBL] [Abstract][Full Text] [Related]
19. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
Wei KK; Zhang LR
Clin Drug Investig; 2015 Sep; 35(9):583-91. PubMed ID: 26293521
[TBL] [Abstract][Full Text] [Related]
20. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.
Eur Heart J; 1999 May; 20(10):725-41. PubMed ID: 10329064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
